PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective

Epithelial ovarian cancer (EOC) has a poor prognosis. Since the introduction of paclitaxel as antineoplastic agent >20 years ago, only a few phase III randomized trials have shown challenging data regarding different therapeutic options for facing its aggressive clinical course and granting activ...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncol Lett
Autors principals: Loizzi, Vera, Ranieri, Girolamo, Laforgia, Mariarita, Gadaleta, Cosmo Damiano, Gargano, Giulio, Kardhashi, Anila, De Liso, Maria, Naglieri, Emanuele, Del Vecchio, Vittoria, Cicinelli, Ettore, Cormio, Gennaro
Format: Artigo
Idioma:Inglês
Publicat: D.A. Spandidos 2020
Matèries:
Review
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7439101/
https://ncbi.nlm.nih.gov/pubmed/32831909
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2020.11951
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars